Phase 3 data published in The Lancet Respiratory Medicine show that high-dose, twice-daily thoracic radiotherapy paired with concurrent chemotherapy holds that promise for patients battling limited-stage SCLC. #lungcancer www.cancernetwork.com/view/high-do... - ThreadSky | a Reddit-style client for Bluesky

alcmi.bsky.social • 36 days ago

Phase 3 data published in The Lancet Respiratory Medicine show that high-dose, twice-daily thoracic radiotherapy paired with concurrent chemotherapy holds that promise for patients battling limited-stage SCLC. #lungcancer

https://www.cancernetwork.com/view/high-dose-radiotherapy-boosts-survival-without-toxicity-increase-in-ls-sclc

Comments